UPDATE 1-AcelRx wins U.S. patents for pain treatment

April 11 Wed Apr 11, 2012 8:42am EDT

April 11 (Reuters) - AcelRx Pharmaceuticals said the U.S. patent office granted two patents on the specialty pharmaceutical company's methods for managing post-operative pain.

AcelRx said the notice of allowance from the U.S. Patent and Trademark Office could provide protection to its NanoTab technology for delivering a pain drug, sufentanil, till at least Feb, 2029.

A Notice of Allowance is issued after the USPTO decides that a patent can be granted after a company has applied for one.

AcelRx's shares closed at $3.40 on Tuesday on the Nasdaq.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.